Cipher Pharmaceuticals Stock EBITDA
| CPH Stock | CAD 14.40 0.16 1.12% |
Cipher Pharmaceuticals fundamentals help investors to digest information that contributes to Cipher Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cipher Stock. The fundamental analysis module provides a way to measure Cipher Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cipher Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 11.3 M | 6.2 M |
Cipher | EBITDA |
Cipher Pharmaceuticals Company EBITDA Analysis
Cipher Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Cipher Pharmaceuticals EBITDA | 11.26 M |
Most of Cipher Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cipher Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cipher EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Cipher Pharmaceuticals is extremely important. It helps to project a fair market value of Cipher Stock properly, considering its historical fundamentals such as EBITDA. Since Cipher Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cipher Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cipher Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Cipher Ebitda
Ebitda |
|
According to the company disclosure, Cipher Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of 11.26 M. This is 98.72% lower than that of the Pharmaceuticals sector and 98.09% lower than that of the Health Care industry. The ebitda for all Canada stocks is 99.71% higher than that of the company.
Cipher EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cipher Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cipher Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cipher Pharmaceuticals by comparing valuation metrics of similar companies.Cipher Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Cipher Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cipher Pharmaceuticals from analyzing Cipher Pharmaceuticals' financial statements. These drivers represent accounts that assess Cipher Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cipher Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 31.0M | 19.7M | 37.2M | 304.5M | 106.4M | 69.3M | |
| Enterprise Value | 34.2M | 12.4M | 17.2M | 276.1M | 66.9M | 60.9M |
Cipher Fundamentals
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0506 | ||||
| Profit Margin | 0.60 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 412.52 M | ||||
| Shares Outstanding | 25.59 M | ||||
| Shares Owned By Insiders | 42.00 % | ||||
| Shares Owned By Institutions | 1.50 % | ||||
| Number Of Shares Shorted | 127.32 K | ||||
| Price To Earning | 21.55 X | ||||
| Price To Book | 2.64 X | ||||
| Price To Sales | 13.93 X | ||||
| Revenue | 21.16 M | ||||
| Gross Profit | 16.68 M | ||||
| EBITDA | 11.26 M | ||||
| Net Income | 20.38 M | ||||
| Cash And Equivalents | 9.25 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 353 K | ||||
| Debt To Equity | 62.30 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 3.86 X | ||||
| Cash Flow From Operations | 16 M | ||||
| Short Ratio | 2.17 X | ||||
| Earnings Per Share | 0.89 X | ||||
| Target Price | 16.7 | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 368.49 M | ||||
| Total Asset | 86.03 M | ||||
| Retained Earnings | 66.27 M | ||||
| Working Capital | 43.02 M | ||||
| Net Asset | 86.03 M |
About Cipher Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cipher Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cipher Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cipher Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cipher Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Cipher Stock
| 0.59 | CHE-UN | Chemtrade Logistics | PairCorr |
| 0.53 | BOFA | Bank of America | PairCorr |
| 0.52 | RY-PS | Royal Bank Earnings Call This Week | PairCorr |
| 0.48 | RY | Royal Bank Earnings Call This Week | PairCorr |
| 0.47 | RY-PN | Royal Bank Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.
The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.